In October of 2013 the University of Delaware along with partners Christiana Care Health System, Nemours/A.I. DuPont Hospital for Children, and the Medical University of South Carolina received $25 million to support the growth of clinical and translational research (CTR) over the next five years.

The purpose of the combined NIH and state of Delaware funding is to build research capacities in States that historically have had low levels of NIH funding by supporting basic, clinical, and translational research through mentoring, education and faculty development, and infrastructure improvements.

This entire effort is known as the Delaware-CTR ACCEL program. Stuart Binder-Macleod, associate vice provost for clinical and translational research, at the University of Delaware leads this program.

The ACCEL program provides resources, networking opportunities, pilot funding, research design and bio-statistical support, mentoring assistance, and community engagement opportunities to help develop, implement, and expand clinical and translational research. Ultimately ACCEL serves to promote the innovation, acceleration, and translation of research that will improve health outcomes, enhance future funding success, accelerate health care quality, actively engage community members, and advance research careers.

For more information about ACCEL, visit the Delaware-CTR ACCEL website.